The cardiovascular-focused pharmaceutical company has raised $94m in equity from investors including strategic partner Sanofi.
MyoKardia, a US-based biopharmaceutical company backed by pharmaceutical firm Sanofi, filed for an initial public offering on Nasdaq on Monday that could raise up to $86.3m.
Founded in 2012, MyoKardia is developing treatments for rare cardiovascular diseases by targeting heritable cardiomyopathies, in which heart failure results from from biomechanical defects in the contraction of the cardiac muscles.
The IPO proceeds will fund the advancement of MyoKardia’s lead product candidate, MYK-461, through Phase 2 clinical trials. Additional capital will support…
